Synova Life Sciences
Healthspan
Maker of the Synova WAVE, an FDA-cleared point-of-care device extracting autologous SVF/adipose stem cells in ~3 minutes for regenerative-medicine clinics.
Synova Life Sciences develops point-of-care technology for autologous regenerative medicine. Its core product, the Synova WAVE, is an automated device that extracts stromal vascular fraction (SVF) — including adipose-derived stem cells — from a patient's own fat tissue at the point of care. Using patented modified-shockwave processing, the closed, sterile system cuts processing to about three minutes and is enzyme- and chemical-free, yielding higher viability (company-reported ~91% median) than the leading competitor. FDA 510(k) cleared (BK251268), it enables minimally invasive, same-day, office-based procedures. Initial applications target osteoarthritis and cartilage regeneration and complementing musculoskeletal surgical repairs, with the company pursuing wider uses including orthopaedic, pulmonary-fibrosis and post-COVID indications.
Research mapping
Healthspan / Intervene (AI) / Seed
Evidence boundary
Original analysis and independent corroboration remain under development. Commercial scale and durable technical advantage remain under review.
What makes it defensible
Patented shockwave-based SVF extraction — enzyme-free, closed, ~3-minute point-of-care processing versus multi-hour enzyme methods, at higher cell viability.
Position in the stack: Point-of-care medical-device OEM enabling same-day autologous regenerative procedures in physician offices.
Who buys it
Founding team
John Chi — Founder & CEO — BS Electrical Engineering (Stanford); MS Biotechnology (Cal State); inventor of the core technology (18 international patents)
Michel Haddad — Co-founder & Chief Commercial Officer — Business development and market entry
SourceFinancing detail
- Last round
- Seed+
Investors: Leonhardt Ventures; Top Doctor Magazine; Renuvion
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
Evidence & media
-
FDA 510(k) BK251268 — Synova Wave Adipose Processing System
What this source supports: FDA 510(k) clearance (Nov 17, 2025) for the Synova WAVE closed-loop adipose processing system for autologous fat transfer (device class 2).
What it does not establish: Clearance covers device safety/equivalence only; no clinical efficacy data and no commercial sales evidence.
Source -
"SAVE" — Shock-Assisted Viable Extraction: A Minimally Manipulative Method (ASJ Open Forum)
What this source supports: Peer-reviewed ASJ Open Forum study used the Synova SAVE/WAVE shockwave device to compare regenerative-cell yields and adipocyte viability.
What it does not establish: Academic method study, not a controlled clinical outcome trial; company-affiliated authors.
Source -
Synova Life Sciences — Creative Destruction Lab profile
What this source supports: CDL profile: automated device extracts stem cells from fat tissue; shockwave process cuts a 3-4 hour process to ~3 minutes yielding ~50% more cells.
What it does not establish: Programme marketing; viability figures are company-reported.
Source -
Synova WAVE — Vail Medical Equipment (distributor)
What this source supports: Distributor page: FDA-cleared automated adipose processing; cites ~90% viability and up to 44% higher viability vs leading mechanical methods.
What it does not establish: Distributor repackages company claims; the "independent third-party validation" is not linked.
Source